# Open-label Long-term Extension Study of Fesoterodine in Japanese Subjects With Neurogenic Detrusor Overactivity.

> **NCT02501928** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 12 (actual)

## Conditions studied

- Urinary Bladder, Neurogenic

## Interventions

- **DRUG:** Fesoterodine PR 4 mg
- **DRUG:** Fesoterodine PR 8 mg
- **DRUG:** Fesoterodine BIC 2 mg
- **DRUG:** Fesoterodine BIC 4 mg

## Key facts

- **NCT ID:** NCT02501928
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-05
- **Primary completion:** 2020-04-01
- **Final completion:** 2020-04-01
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2020-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02501928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02501928, "Open-label Long-term Extension Study of Fesoterodine in Japanese Subjects With Neurogenic Detrusor Overactivity.". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02501928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*